Yahoo
OTC Markets OTCPK - Delayed Quote USD

Bavarian Nordic A/S (BVNRY)

12.30 +0.23 (+1.91%)
At close: November 4 at 1:53:19 PM EST
Chart Range Bar
Loading chart for BVNRY
  • Previous Close 12.07
  • Open 12.40
  • Bid 12.30 x 250000
  • Ask 12.36 x 20000
  • Day's Range 12.30 - 12.40
  • 52 Week Range 8.67 - 12.72
  • Volume 136
  • Avg. Volume 3,223
  • Market Cap (intraday) 2.753B
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) 12.18
  • EPS (TTM) 1.01
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Mar 27, 2020
  • 1y Target Est --

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,906

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

BVNRY
23.92%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

1-Year Return

BVNRY
2.59%
OMX Copenhagen 25 Index (^OMXC25)
20.47%

3-Year Return

BVNRY
5.31%
OMX Copenhagen 25 Index (^OMXC25)
23.96%

5-Year Return

BVNRY
5.31%
OMX Copenhagen 25 Index (^OMXC25)
1.78%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 2.03B
Earnings 731.64M
Profit Margin 35.97%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
500M
1B
2B
2B
-20.0%
0.0%
20.0%
40.0%
60.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    24.34%

  • Return on Assets (ttm)

    5.01%

  • Return on Equity (ttm)

    12.21%

  • Revenue (ttm)

    6.34B

  • Net Income Avi to Common (ttm)

    1.54B

  • Diluted EPS (ttm)

    1.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.36B

  • Total Debt/Equity (mrq)

    0.99%

  • Levered Free Cash Flow (ttm)

    109.42M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: